- Home
- MYGN vs MLYS Comparison
MYGN vs MLYS Comparison
Compare MYGN & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- MLYS
- Stock Information
- Founded
- MYGN 1991
- MLYS 2019
- Country
- MYGN United States
- MLYS United States
- Employees
- MYGN N/A
- MLYS N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- MYGN Health Care
- MLYS Health Care
- Exchange
- MYGN Nasdaq
- MLYS Nasdaq
- Market Cap
- MYGN 744.7M
- MLYS 893.0M
- IPO Year
- MYGN 1995
- MLYS 2023
- Fundamental
- Price
- MYGN $7.29
- MLYS $13.53
- Analyst Decision
- MYGN Hold
- MLYS Strong Buy
- Analyst Count
- MYGN 16
- MLYS 3
- Target Price
- MYGN $20.17
- MLYS $33.00
- AVG Volume (30 Days)
- MYGN 1.2M
- MLYS 1.2M
- Earning Date
- MYGN 05-06-2025
- MLYS 05-08-2025
- Dividend Yield
- MYGN N/A
- MLYS N/A
- EPS Growth
- MYGN N/A
- MLYS N/A
- EPS
- MYGN N/A
- MLYS N/A
- Revenue
- MYGN $837,600,000.00
- MLYS N/A
- Revenue This Year
- MYGN $2.99
- MLYS N/A
- Revenue Next Year
- MYGN $8.36
- MLYS N/A
- P/E Ratio
- MYGN N/A
- MLYS N/A
- Revenue Growth
- MYGN 11.21
- MLYS N/A
- 52 Week Low
- MYGN $7.35
- MLYS $8.24
- 52 Week High
- MYGN $29.30
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- MYGN 25.95
- MLYS 51.00
- Support Level
- MYGN $7.69
- MLYS $12.77
- Resistance Level
- MYGN $8.27
- MLYS $14.83
- Average True Range (ATR)
- MYGN 0.56
- MLYS 1.17
- MACD
- MYGN 0.02
- MLYS -0.09
- Stochastic Oscillator
- MYGN 1.02
- MLYS 70.39
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.